Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score

Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score

A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker for diagnosis of pleural mesothelioma (PM) and the most used for monitoring treatment. Radiological assessment of PM, based on modified RECIST (mRECIST) criteria, is challenging. This pilot study was designed to evaluate...

Full description

Saved in:
Bibliographic Details
Main Authors: Federica Grosso, Matilde Mannucci, Francesca Ugo, Paola Ferro, Maurizio Cassinari, Antonella Vigani, Antonina Maria De Angelis, Sara Delfanti, Michela Lia, Roberto Guaschino, Stefano Barbero, Silvio Roncella, Ugo Giannoni, Marinella Bertolotti, Maria Pia Pistillo, Vincenzo Fontana
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
mesothelioma
mesothelin
serum biomarkers
modified RECIST
longitudinal study
Medicine (General)
R5-920
Online Access:https://doaj.org/article/28405c6350474f358c3d863dfe112cdc
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/28405c6350474f358c3d863dfe112cdc

Similar Items